GVS (GVS) Q3 2024 earnings summary

Executive summary

• Consolidated revenues reached €321.7 million for the first nine months of 2024, up 3.7% at constant exchange rates year-over-year, with Q3 organic growth of 8.1% driven by Healthcare acceleration.

• Adjusted EBITDA rose 13.0% to €78.1 million, with margin improving to 24.3%, a 220 basis point increase from the prior year.

• Adjusted net income grew 20.5% to €33.9 million, with margin increasing to 10.5% from 9.0%.

• Leverage ratio improved to 2.30x from 2.65x at year-end 2023, reflecting strong financial discipline and supporting deleveraging targets.

• Consistent performance across divisions, with Healthcare & Life Sciences and Safety showing solid growth, while Energy & Mobility remains challenged.

Financial highlights

• Organic sales growth of 3.7% year-over-year, with Q3 2024 showing 8.1% organic growth.

• Adjusted EBITDA margin improved to 24.3% from 22.1% in 9M 2023.

• Adjusted net income margin increased to 10.5% from 9.0% year-over-year.

• Net working capital absorption in Q3 linked to higher trade and tax receivables; expected to normalize by year-end.

• CapEx included €5.2 million for a new Chinese plant, with total CapEx around €27.9 million or 6% of turnover.

Outlook and guidance

• FY 2024 organic sales growth expected at 2%-3% over FY 2023.

• Adjusted EBITDA margin to improve by 180-220 basis points versus FY 2023.

• Leverage ratio expected to be around 2x by year-end 2024.

• 2025 outlook remains cautious, with focus on executing the industrial plan and adapting to market/geopolitical conditions.

• Margin improvement in 2025 expected from internal efficiencies and cost reductions, even if top-line growth remains modest.